Cereno Scientific speaks at the PVRI’s 8th Annual Drug Discovery & Development Symposium
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company will participate at the 8th Annual Drug Discovery & Development Symposium arranged by the Pulmonary Vascular Research Institute (PVRI) on July 10-11, 2023. Raymond Benza, PI of the Phase II study of CS1 and member of Cereno’s scientific advisory board, co-chairs the event while Björn Dahlöf, Cereno’s Chief Medical Officer (CMO), will present.Raymond Benza will speak in several sessions about pulmonary hypertension (PAH) and